Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

4.85USD
13 Dec 2017
Change (% chg)

$0.34 (+7.54%)
Prev Close
$4.51
Open
$4.52
Day's High
$4.95
Day's Low
$4.52
Volume
3,952
Avg. Vol
6,282
52-wk High
$8.18
52-wk Low
$4.17

Select another date:

Tue, Dec 5 2017

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

BRIEF-Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn

* Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language

BRIEF-Sonoma Pharmaceuticals files for mixed shelf of upto $75 mln - SEC filing ‍​

* Sonoma Pharmaceuticals Inc files for mixed shelf of upto $75 million - SEC filing ‍​ Source text: (http://bit.ly/2hfgJ1s) Further company coverage:

BRIEF-Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​

* Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million

BRIEF-Sonoma Pharmaceuticals receives Brazilian approvals

* Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products

BRIEF-Sonoma Pharmaceuticals to commercialize company's new Loyon product in U.S.

* Announced U.S. commercialization of company's new Loyon product

BRIEF-Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

* Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

BRIEF-Sonoma Pharmaceuticals Inc - qtrly‍ net loss per share basic and diluted, continuing operations $0.82​

* Sonoma Pharmaceuticals reports financial results for first quarter of fiscal year 2018

Select another date: